GemPharmatech Co., Ltd. (SHA:688046)
China · Delayed Price · Currency is CNY 37.94
+2.96 (8.46%)
At close: Sep 30, 2026
GemPharmatech Revenue
GemPharmatech had revenue of 251.47M CNY in the quarter ending June 30, 2026, with 23.30% growth. This brings the company's revenue in the last twelve months to 878.13M, up 21.75% year-over-year. In the year 2025, GemPharmatech had annual revenue of 793.39M with 15.51% growth.
Revenue (ttm)
878.13M
Revenue Growth
+21.75%
P/S Ratio
17.68
Revenue / Employee
518.99K
Employees
1,692
Market Cap
15.52B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 793.39M | 106.55M | 15.51% |
| Dec 31, 2024 | 686.84M | 64.65M | 10.39% |
| Dec 31, 2023 | 622.19M | 105.64M | 20.45% |
| Dec 31, 2022 | 516.55M | 122.76M | 31.17% |
| Dec 31, 2021 | 393.79M | 131.87M | 50.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Yili Chuanning Biotechnology | 4.37B |
| Anhui Anke Biotechnology (Group) | 2.45B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Jinyu Bio-technology | 1.53B |
| Nanjing Vazyme Biotech | 1.47B |
| Shanghai Medicilon | 1.38B |
| BrightGene Bio-Medical Technology | 1.36B |
| Sinocelltech Group | 1.25B |